Retroperitoneal and Mesenteric Liposarcomas.
Surg Oncol Clin N Am
; 31(3): 399-417, 2022 07.
Article
in En
| MEDLINE
| ID: mdl-35715141
ABSTRACT
Retroperitoneal liposarcomas are a rare entity and are comprised mostly of the well-differentiated and dedifferentiated subtypes. Eight-year survival ranges from 30% to 80% depending on histologic subtype and grade. Surgery is the cornerstone of treatment and compartment resection is the current standard. Mesenteric liposarcomas are extremely rare and comprise more high-grade lesions, with poorer prognosis of 50% 5-year overall survival. They are managed with a similar aggressive surgical approach. This review presents the current management of retroperitoneal and mesenteric liposarcomas.
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Retroperitoneal Neoplasms
/
Liposarcoma
Limits:
Humans
Language:
En
Journal:
Surg Oncol Clin N Am
Journal subject:
NEOPLASIAS
Year:
2022
Document type:
Article